Certara’s evidence and access group provided guidance about market opportunity for Product X by estimating its peak share, price and access in the initial indication of relapse/refractory disease and the subsequent indication in newly diagnosed patients.

CS Opportunity Assessment 1

Certara’s evidence and access group provided guidance about market opportunity

In-depth interviews with 30 KOLs and 16 payers in the US, France and Germany.

  • Diagnosis and treatment of this rare disease in 3 markets highlighting similarities and differences
  • Estimates of prevalence and distribution of patients by disease type
  • Comprehensive product assessment by KOLs and payers and expected utilization
  • Price recommendation by market
  • Findings were used by the client to plan the Phase III deliverable
  • The Client gained organizational alignment on a price and access case that provided the client with an upside to their internal forecast, supporting additional investment in evidence-generation to achieve that upside case
CS Opportunity Assessment 2

お手伝いできることはありませんか?

トップに戻る
Powered by Translations.com GlobalLink OneLink Software